SGLT-2 Inhibitors and Nephrolithiasis Risk: 1 A Meta-Analysis
Result. We have included a total of 11635698 participants who experienced nephrolithiasis 44 from a total of six clinical studies with nephrolithiasis rates of 1,27% in the SGLT2i group (n 45 = 739197), compared to 1,56% in the control arm (n = 10896501). SGLT-2 inhibitor therapy 46 has been associated with a lower risk for nephrolithiasis compared … Leggi tutto